Special Article

You have full text access to this OnlineOpen article

American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis

  1. Carol A. Wallace1,*,
  2. Edward H. Giannini2,
  3. Bin Huang2,
  4. Lukasz Itert2,
  5. Nicolino Ruperto3,†,
  6. Childhood Arthritis Rheumatology Research Alliance (CARRA),
  7. Pediatric Rheumatology Collaborative Study Group (PRCSG),
  8. Paediatric Rheumatology International Trials Organisation (PRINTO)

Article first published online: 29 JUN 2011

DOI: 10.1002/acr.20497

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 63, Issue 7, pages 929–936, July 2011

Additional Information

How to Cite

Wallace, C. A., Giannini, E. H., Huang, B., Itert, L., Ruperto, N., Childhood Arthritis Rheumatology Research Alliance (CARRA), Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) (2011), American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res, 63: 929–936. doi: 10.1002/acr.20497

Author Information

  1. 1

    Seattle Children's Hospital and University of Washington School of Medicine, Seattle

  2. 2

    Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio

  3. 3

    IRCCS G. Gaslini, Pediatria II Reumatologia, Paediatric Rheumatology International Trials Organisation, Genoa, Italy

  1. †

    Dr. Ruperto has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Bristol-Myers Squibb and Roche.

*University of Washington School of Medicine, Division of Rheumatology – Pediatrics, Seattle Children's Hospital, 4800 Sand Point Way NE R-5420, Seattle, WA 98104

  1. †

    Dr. Ruperto has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Bristol-Myers Squibb and Roche.

Publication History

  1. Issue published online: 29 JUN 2011
  2. Article first published online: 29 JUN 2011
  3. Manuscript Accepted: 17 NOV 2010
  4. Manuscript Received: 15 JAN 2010

Funded by

  • Centocor through the investigator-initiated study program
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH. Grant Number: P60-AR-44059

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (129K)

REFERENCES

  • 1
    Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763–9.
  • 2
    Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007; 56: 3096–106.
    Direct Link:
  • 3
    Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al, for the Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58: 1496–504.
    Direct Link:
  • 4
    Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810–20.
  • 5
    Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383–91.
  • 6
    Raine R, Sanderson C, Hutchings A, Carter S, Larkin K, Black N. An experimental study of determinants of group judgments in clinical guideline development. Lancet 2004; 364: 429–37.
  • 7
    Bowles N. The Delphi technique. Nurs Stand 1999; 13: 32–6.
  • 8
    Horton JN. Nominal group technique: a method of decision-making by committee. Anaesthesia 1980; 35: 811–4.
    Direct Link:
  • 9
    Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290–4.
  • 10
    Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology [editorial]. J Rheumatol 1998; 25: 198–9.
  • 11
    Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 3554–62.
    Direct Link:
  • 12
    Wallace CA, Ravelli A, Huang B, Giannini EH. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol 2006; 33: 789–95.
  • 13
    Oen K. Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2002; 16: 347–60.
  • 14
    Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J Rheumatol 2003; 30: 579–84.
  • 15
    Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003; 30: 386–93.
  • 16
    Knowlton N, Jiang K, Frank MB, Aggarwal A, Wallace C, McKee R, et al. The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum 2009; 60: 892–900.
    Direct Link:
  • 17
    Classification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures. Development of classification and response criteria for rheumatic diseases [editorial]. Arthritis Rheum 2006; 55: 348–52.
    Direct Link:
  • 18
    Bombardier C, Tugwell P. A methodological framework to develop and select indices for clinical trials: statistical and judgmental approaches. J Rheumatol 1982; 9: 753–7.
  • 19
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35.
    Direct Link:
  • 20
    Magni-Manzoni S, Ruperto N, Pistorio A, Sala E, Solari N, Palmisani E, et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008; 59: 1120–7.
    Direct Link:
  • 21
    Ruperto N, Ravelli A, Oliveira S, Alessio M, Mihaylova D, Pasic S, et al, for the Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement. Arthritis Rheum 2006; 55: 355–63.
    Direct Link:
  • 22
    Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202–9.
  • 23
    Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50: 2281–90.
    Direct Link:
  • 24
    Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008; 67: 703–9.
  • 25
    Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull 1971; 76: 378–82.
  • 26
    Davies EH, Surtees R, DeVile C, Schoon I, Vellodi A. A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis 2007; 30: 768–82.
  • 27
    Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159–74.
  • 28
    Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005; 140: 509–16.
  • 29
    Cassidy JT, Levinson JE, Brewer EJ Jr. The development of classification criteria for children with juvenile rheumatoid arthritis. Bull Rheum Dis 1989; 38: 1–7.
  • 30
    Van Tuyl LH, Vlad SC, Felson DT, Wells G, Boers M. Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum 2009; 61: 704–10.
    Direct Link:
  • 31
    Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573–86.
    Direct Link:
  • 32
    Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al, for the Paediatric Rheumatology International Trials Organization (PRINTO). Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010; 303: 1266–73.
View Full Article (HTML) Get PDF (129K)